Showing 4311-4320 of 5659 results for "".
- Diclofenac, Silymarin Show Promise for Preventing Chemotherapy-Induced Hand-Foot Syndrome: Meta-analysishttps://practicaldermatology.com/news/diclofenac-silymarin-show-promise-for-preventing-chemotherapy-induced-hand-foot-syndrome-meta-analysis/2485939/Diclofenac and topical silymarin reduced the risk of grade 2 or higher chemotherapy-induced hand-foot syndrome (HFS), according to a new meta-analysis of randomized clinical trials evaluating pharmacologic preventive strategies.
- Arcutis Launches First-in-Human Trial of CD200R Agonist ARQ-234 in Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-first-in-human-trial-of-cd200r-agonist-arq-234-in-atopic-dermatitis/2485894/Arcutis Biotherapeutics announced today that it has enrolled the first participant in a phase 1a/1b clinical trial evaluating ARQ-234, an investigational CD200 receptor (CD200R) agonist, in healthy volunteers and adults with moderate to severe atopic dermatitis (AD
- EMA Panel Backs Baricitinib for Adolescents With Severe Alopecia Areatahttps://practicaldermatology.com/news/ema-panel-backs-baricitinib-for-adolescents-with-severe-alopecia-areata/2485850/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of baricitinib (Olumiant, Eli Lilly and Company), a once-daily oral Janus kinase (JAK) inhibitor, for adolescents aged 12 to yo
- Most Nations Off Track to Meet 2030 Skin NTD SDG Targets: Reporthttps://practicaldermatology.com/news/most-nations-off-track-to-meet-2030-skin-ntd-sdg-targets-report/2485823/A new report in JAMA Dermatology revealed that most countries are unlikely to achieve the World Health Organization (WHO) target of a 75% reduction in disability-adjusted life-years (DALYs) from skin-related neglected tropical diseases (NTDs) from 2020 lev
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://practicaldermatology.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin
- Staphylococcus aureus Implicated as Central Driver of Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/staphylococcus-aureus-implicated-as-central-driver-of-pediatric-atopic-dermatitis/2485614/A comprehensive literature analysis presented at the South Beach Symposium identified Staphylococcus aureus as a key contributor to pediatric atopic dermatitis (AD) pathogenesis, extending beyond disease exacerbation to underlying inflammation and prurit
- Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypeshttps://practicaldermatology.com/news/delgocitinib-improves-patient-reported-outcomes-across-chronic-hand-eczema-subtypes/2485611/Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette,
- FDA Accepts Galderma’s RelabotulinumtoxinA BLA Resubmissionhttps://practicaldermatology.com/news/fda-accepts-galdermas-relabotulinumtoxina-bla-resubmission/2485601/Galderma announced that the US Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess™) for the temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines in a
- Empowering the HS Community Through Wellness, Nutrition, and Compassionhttps://practicaldermatology.com/news/empowering-the-hs-community-through-wellness-nutrition-and-compassion/2485555/Wellness goes beyond skin when it comes to managing hidradenitis suppurativa (HS). In an effort to spread awareness of that concept, HS Connect founder and CEO Brindley Brooks and COO Cristina Curp took the stage at
- Arcutis Reports Positive Phase 2 Data for Infant Atopic Dermatitis Programhttps://practicaldermatology.com/news/arcutis-reports-positive-phase-2-data-for-infant-atopic-dermatitis-program/2485557/Arcutis Biotherapeutics reported positive topline results from the phase 2 INTEGUMENT-INFANT trial evaluating investigational ZORYVE® (roflumilast) cream 0.05% in infants aged 3 months to younger than 24 months with mild to moderate atopic dermatitis (AD).